Lupus Anticoagulant Measurement

  • I. J. Mackie
  • S. Donohoe
  • S. J. Machin


In 1952, Conley and Hartman described patients with haemorrhagic symptoms, whose plasma prolonged the whole blood clotting time and failed to correct on the addition of normal plasma. Further patients were reported and in 1972 the term “lupus anticoagulant” was coined [1], as the apparent inhibitor of coagulation had been observed in patients with systemic lupus erythematosus (SLE). Unfortunately, the term lupus anticoagulant (LA) is a misnomer, as delayed coagulation is only observed in vitro, and hemorrhage in patients with LA is rare. The phenomenon is not confined to SLE and has been observed in patients with a wide range of disease states as well as asymptomatic, apparently healthy subjects. LA appears to be due to certain acquired immunoglobulins of varying class that interact with prothrombin/ phospholipid and β 2-glycoprotein I/phospholipid complexes in a manner that influences phospholipid-dependent in vitro coagulation tests. There may also be additional target proteins involved.


Systemic Lupus Erythematosus Normal Plasma Lupus Anticoagulant Confirmation Step Thromboplastin Reagent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1: 75–95.PubMedGoogle Scholar
  2. 2.
    Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885–889.CrossRefGoogle Scholar
  3. 3.
    Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;108:in press.Google Scholar
  4. 4.
    Exner T, Triplett DA, Taberner D et al. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65: 320–322.PubMedGoogle Scholar
  5. 5.
    Brandt JT, Triplett DA, Alving B et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185–1190.PubMedGoogle Scholar
  6. 6.
    Lawrie A., Mackie I, Purdy G et al. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999; 81: 758–762.PubMedGoogle Scholar
  7. 7.
    Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time–the central role of phosphatidylserine. Thromb Haemost 1984; 52: 172–175.PubMedGoogle Scholar
  8. 8.
    Brandt JT, Triplett DA, Musgrave K et al. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants. Arch Pathol Lab Med 1987; 111: 120–124.PubMedGoogle Scholar
  9. 9.
    Brandt JT, Triplett DA, Rock WA et al. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program. Arch Pathol Lab Med 1991; 115: 109–114.PubMedGoogle Scholar
  10. 10.
    Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen aPTT reagents for the presence of lupus anticoagulants. Haemostasis 1995; 25: 98–105.PubMedGoogle Scholar
  11. 11.
    Brancaccio V, Ames PR, Glynn J et al. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive aPTT reagent. Blood Coagul Fibrinolysis 1997; 8: 155–160.PubMedCrossRefGoogle Scholar
  12. 12.
    Lawrie AS, Purdy G, Mackie IJ et al. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997; 98: 887–892.PubMedCrossRefGoogle Scholar
  13. 13.
    Rauch J., Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892–896.PubMedGoogle Scholar
  14. 14.
    Alving BM, Barr CF, Johansen LE et al. Comparison between a one-point dilute phospholipid aPTT and the dilute Russell viper venom time for verification of lupus anticoagulants. Thromb Haemost. 1992; 67: 672–678.PubMedGoogle Scholar
  15. 15.
    Jacobsen EM, Barna-Cler L, Taylor JM et al. Lupus ratio: an international inter-laboratory study using an intergrated test for lupus anticoagulant (LA). Lupus 1998; 7 (Suppl 2): S216.Google Scholar
  16. 16.
    Triplett DA, Brandt JT, Kaczor D et al. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678–682.PubMedGoogle Scholar
  17. 17.
    Exner T, Rickard A, Kronberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 1979; 40: 143–151.CrossRefGoogle Scholar
  18. 18.
    Chantarangkul V, Tripodi A, Arbini A et al. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992; 67: 355–365.PubMedCrossRefGoogle Scholar
  19. 19.
    Schleider MA, Nachman RL, Jaffe EA et al. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499–509.PubMedGoogle Scholar
  20. 20.
    Arnout J, Vanrusselt M, Huybrechts E et al. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94–99.PubMedCrossRefGoogle Scholar
  21. 21.
    Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb Haemost 1994; 72: 728–733.PubMedGoogle Scholar
  22. 22.
    Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869–874.PubMedGoogle Scholar
  23. 23.
    Arnout J, Huybrechts E, Vanrusselt M et al. A new lupus anticoagulant neutralization test based on platelet-derived vesicles. Br J Haematol 1992; 80: 341–346.PubMedCrossRefGoogle Scholar
  24. 24.
    Medical Devices Agency (MDA) Evaluation of lupus anticoagulant kits. London: Department of Health, MDA, ISDN No. 1 85839 918 1, 1998, No 43.Google Scholar
  25. 25.
    Speijer H, Govers-Riemslag JW, Zwaal RF et al. Prothrombin activation by an activator from the venom of Oxyuranus scutellatus (Taipan snake). J Biol Chem 1986; 261: 13258–13267.PubMedGoogle Scholar
  26. 26.
    Rooney AM, McNally T, Mackie IJ et al. The Taipan snake venom time: a new test for lupus anticoagulant. J. Clin. Pathol 1994; 47: 497–501.PubMedCrossRefGoogle Scholar
  27. 27.
    Triplett DA, Stocker KF, Unger GA et al. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925–931.PubMedGoogle Scholar
  28. 28.
    Gray E, Mackie I, Greaves M. Calibration of the 1st British reference plasma panel for lupus anticoagulants. Br J Haematol 1998; 105 (suppl 1): 97.Google Scholar
  29. 29.
    Arnout J, Vanrusselt M, Wittevrongel C et al. Monoclonal antibodies against beta-2-glycoprotein I: use as reference material for lupus anticoagulant tests. Thromb Haemost 1998; 79: 955–958.PubMedGoogle Scholar
  30. 30.
    Jennings I, Kitchen S, Woods TA et al. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997; 77: 934–937.PubMedGoogle Scholar
  31. 31.
    MacLean MA, Cumming GP, McCall F et al. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101: 103–106.PubMedCrossRefGoogle Scholar
  32. 32.
    Rai RS, Regan L, Clifford K et al. Antiphospholipid antibodies and ß2-glycoprotein-1 in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10: 2001–2005.PubMedGoogle Scholar
  33. 33.
    Rai RS, Clifford K, Cohen H et al. High prespective fetal loss in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10: 3301–3304.PubMedGoogle Scholar
  34. 34.
    Kwak JYH, Barini R, Gilman-Sachs A et al. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome. Am J Obstet Gynaecol 1994; 171: 239–246.Google Scholar
  35. 35.
    Galli M, Finazzi G, Norbis F et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81: 695–700.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2000

Authors and Affiliations

  • I. J. Mackie
  • S. Donohoe
  • S. J. Machin

There are no affiliations available

Personalised recommendations